

The elements of human cyclin D1 promoter and regulation involved

Zhi-yi Guo · Xiao-hui Hao · Fei-Fei Tan · Xin Pei ·
Li-Mei Shang · Xue-lian Jiang · Fang Yang

Received: 22 August 2010 / Accepted: 7 December 2010 / Published online: 11 February 2011
© Springer-Verlag 2011

Abstract Cyclin D1 is a cell cycle machine, a sensor of extracellular signals and plays an important role in G1-S phase progression. The human cyclin D1 promoter contains multiple transcription factor binding sites such as AP-1, NF- κ B, E2F, Oct-1, and so on. The extracellular signals functions through the signal transduction pathways converging at the binding sites to active or inhibit the promoter activity and regulate the cell cycle progression. Different signal transduction pathways regulate the promoter at different time to get the correct cell cycle switch. Disorder regulation or special extracellular stimuli can result in cell cycle out of control through the promoter activity regulation. Epigenetic modifications such as DNA methylation and histone acetylation may involved in cyclin D1 transcriptional regulation.

Keywords Promoter · Transcription factor · Signal transduction pathway · Epigenetic regulation

Introduction

During the G1 phase, cells will response to the extracellular signals that influence cell division, growth, and differentiation. Cyclin D1 is thought to play pivotal roles in G1-S phase transition. Mistakes in G1 phase may lead to cell cycle out of control and cause tumorigenesis. Cyclin D1 is a sensor to integrate extracellular signals with the cell cycle machinery, with functions through CDK4/6 to trigger cell cycle progres-

sion. In recent years, accumulating evidence suggests cyclin D1 also convey cell cycle or CDK-independent functions, and cell can do without cyclin D1 (Coqueret 2002; Fu et al. 2004; Lamb et al. 2003; Pestell et al. 1999).

The cyclin D1 promoter sequence was studied and subcloned in several different laboratories (Albanese et al. 1995; Herber et al. 1994b; Motokura and Arnold 1993; Nagata et al. 2001). The promoter sequence, GenBank number Z29078 (Herber et al. 1994b), contains no obvious TATA box with TF (transcription factor) binding sites such as AP-1, SP-1, E2F, OCT-1, and so on. In this review, the structure of cyclin D1 promoter is discussed with such binding sites, and regulation from signal transduction pathway converging at the binding site.

The elements of the cyclin D1 promoter

Cyclin D1 promoter popularly studied is 1,810 bp about with many *cis*-elements that can mediate signals activate or inactivate the promoter activity. From -1,309 (NFAT binding site) to -10 (Ets binding site), there are many regulatory elements reported. And if searching by computer program, there are some more elements that have not yet been studied. To compare the cyclin D1 promoter with rat and mouse, homologues region were found (Eto 2000), which can lead us to find new elements in human cyclin D1 promoter. The elements reviewed here only include the elements that have been studied (Fig. 1; Table 1).

AP1

AP1 site was identified in the promoter, which locates in -954 (Albanese et al. 1999). The site may be assigned TRE (12-O-tetradecanoylphorbol-13-acetate, TPA) response elements.

Z.-y. Guo (✉) · X.-h. Hao · F.-F. Tan · X. Pei · L.-M. Shang ·
X.-l. Jiang · F. Yang
Experimental and Research Center, Hebei United University,
№ 57 JianShe South Road,
TangShan, Hebei 063000, People's Republic of China
e-mail: guozhiyiguo@yahoo.com




Fig. 1 Schematic representation of the elements of human cyclin D1 promoter. Elements of human cyclin D1 promoter are represented by *different colors*. Detail sequences of complex motifs such as ERGE (including AP-1, Oct-1, and YY-1) and Oct1-GAS are showed.

Sequence of Egr-1 and Sp1 are also showed. Starting site of transcription is by *two arrows* due to the data of the referenced papers, and the sequences are showed in the manuscript

API family protein, such as c-Fos, c-Jun, JunB, JunD, ATF, Fra-1, Fra-2, and so on, can bind at this site by forming homo- or heter-dimer (Fig. 1).

c-Jun (Albanese et al. 1995; Cicatiello et al. 2004; Mechta et al. 1997; Soh and Weinstein 2003) Fra-1 (Burch

et al. 2004; Mechta et al. 1997) Fra-2 (Balmanno and Cook 1999) can activate cyclin D1 transcription. ATF3 (Allan et al. 2001) activate cyclin D1 promoter activity requiring cAMP response element-binding (CREB) site involved although it directly bind to AP-1 site. c-Fos may sometime

Table 1 Positions of TF elements in human cyclin D1 promoter

elements	location	reference
CREB/ATF2	-58	J Biol Chem, 1999 .274(11):7341
Lef/Tcf 4	-82	J Boil Chem, 2002 .277(48):45847
Sp-1	-113, -119	J Biol Chem, 1997 .272(52):33181
Egr	-137, -118	J Biol Chem, 1997 .272(52):33181
E2F	-148	Mol Cell Biol, 2000. 20(2): 672
GAS	-478, -144	Mol Cell Biol, 2003. 23(24): 8934–45
Oct_1	-252	Mol Cell Biol, 2003. 23(24): 8934–45
GT-boxA	-494	Mol Cell, 2003.11(6):1503
CSL	-525	Mol Cell Biol, 2001. 21(17): 5925
E-box	-588	Epigenetics, 2009.4(7):487–99
Ets	-779	Mol Biol Cell, 2001.12(12):4066
Oct_1	-941	Mol Cell Biol, 2004.24(16):7260
YY-1	-945	Mol Cell Biol, 2004.24(16):7260
AP-1	-952	Mol Cell Biol, 2004.24(16):7260
ERGE	-952	Mol Cell Biol, 2004.24(16):7260
NFAT	-1,309	J Biol Chem, 2009.284:36302-36311

Elements locations in human cyclin D1 promoter here are normalized to the paper (Motokura and Arnold 1993) and may be some different to the reference showed in the table

depress (Albanese et al. 1995) or activate (Brown et al. 1998; Cicatiello et al. 2004; Watanabe et al. 1996b) cyclin D1 promoter. JunB usually inhibits cyclin D1 promoter and can antagonized the c-Jun activation of cyclin D1 promoter (Shaulian and Karin 2001). A change of AP-1 composition toward an increase of JunB results in downregulation of cyclin D1 (Grosch et al. 2003). So generally c-Jun is an activator and JunB a repressor of cyclin D1 promoter. c-Fos is expressed rapidly and transiently (Balmanno and Cook 1999), so the inhibition effect by c-Fos overexpression (Albanese et al. 1995) probably cannot function in real cell cycle, except for c-Fos prolonged binding by some stimulation, e.g., oxidative stress (Burch et al. 2004).

Not only protein level but also the phosphorylated modification status is important to AP-1 proteins. c-Jun activation of cyclin D1 promoter requires phosphorylated on Ser63/73-Pro motifs (Wulf et al. 2001). Phosphorylation of JunB results in decreased JunB protein levels in mitotic and early G1 cells. In contrast, c-Jun levels remain constant with N-terminal phosphorylation. And the modifications of AP-1 proteins may regulate cyclin D1 transcription temporally to control cell cycle progression (Bakiri et al. 2000).

Some TFs in addition to Ap-1 family may regulate cyclin D1 promoter activity through AP-1 site directly (Roche et al. 2004) or indirectly, e.g., by protein interaction (Albanese et al. 1999), cooperation with other TF binding sites such as CREB (Watanabe et al. 1996a).

GAS

Among the STATs, only STAT3 and STAT5 can bring about the activation of cyclin D1 (Bromberg et al. 1999; Calo et al. 2003; Leslie et al. 2006).

Literatures showed that activated form of STAT3 was accompanied by increased expression levels of cyclin D1 (Bromberg et al. 1999; Kijima et al. 2002; Leslie et al. 2006; Masuda et al. 2001, 2002). And some paper showed that STAT3 can inhibit cyclin D1 expression (Zhang et al. 2003). And during the liver regeneration after partial hepatectomy, the cyclin D1 induction was repressed, but STAT3 was unchanged in mice (Chen et al. 2004), which may suggest that modification of STAT3 is important to its activity. Data also showed cyclin D1 overexpression and STAT3 activation were, mutually exclusive events in MM (Quintanilla-Martinez et al. 2003).

But there was no evidence showing STAT3 can directly function through the cyclin D1 promoter, lacking data such as EMSA, ChIP and so on (Masuda et al. 2001, 2002). Moreover, cyclin D1 repression may due to CDKN1A or CDKN1B promoter induction. There are some evidences shows that STAT3 can active CDKN1B or CDKN1A promoter through PI3K pathway. Clearly, PI3K pathway can induce cyclin D1 promoter, and new evidences

(Bienvenu et al. 2005) show that cyclin D1 is recruited to the CDKN1A promoter by a STAT3-NcoA complex leading to an inhibition of the p21waf1 gene (Bienvenu et al. 2005). In conclusion, in some context STAT3 and cyclin D1 balanced in cell cycle regulation but generally the relation between cyclin D1 and STAT3 may due to cell type and now is unclear.

Unlike STAT3, STAT5 can directly bind cyclin D1 promoter in which there are two STAT binding sites, one called GAS1 the other is GAS2 (Magne et al. 2003). The GAS1 site (distal) can bind stat5a/b which can activate cyclin D1 promoter (Brockman et al. 2002; Magne et al. 2003; Matsumura et al. 1999). The phosphorylated modification of STAT5b at Tyr679 induces STAT5b activation and then activate cyclin D1 promoter through interaction with other transcription factors, such as LEF1 and CREB/ATF2 (Kabotyanski and Rosen 2003). STAT5a lacks the Tyr679 site which can explain why only STAT5a/5b heterodimer or STAT5b/5b homodimer but not STAT5a/5a homodimer bind to the cyclin D1 promoter (Magne et al. 2003). Unlike GAS1, the GAS2 site, accurately composite Oct-GAS element, may be masked by Oct-1 protein which binding site overlap with GAS2. The binding of STAT5 to this site is required both GAS2 and OCT-1 element, with the interaction between STAT and PAU domain of Oct-1 (Magne et al. 2003).

E2F

The E2F binding sites in cyclin D1 promoter illustrate Fig. 1. Among five members of the E2F family, including E2F1, 2, 3, 4, and 5, only E2F1 and E2F4 can bind this promoter (Watanabe et al. 1998). E2F transcription factors are bound to RB protein, and when RB is phosphalated by cyclin D1/CDK4, 6, E2Fs are released free. The free E2Fs then regulate their target genes promoting cell cycle progression.

Cyclin D1/CDK4, 6, RB and E2F cooperate together to enter cell cycle and progression in normal cell or to be transformed in tumor cell lines. Although cyclin D1 is upstream upon E2F protein during cell cycle, there are three feedbacks loop between cyclin D1 and E2F to facilitate the progression. E2F4 expresses at early G1 phase (Muller et al. 1997) which can activate cyclin D1 and results in more E2F4 protein level. This is a positive feedback loop, which occurs at early phase of cell cycle and let cell enter cell cycle quickly. There are also two other feedback loops, which respectively result in cell cycle arrest or progression depending cell types. E2F4 and E2F1 are functionally different which also express at different time in cell cycle (Muller et al. 1997). Contrast to E2F4, E2F1 expresses at late G1 phase (Muller et al. 1997). E2F1 regulates a set of genes that can let cell cycle progression. Depending different cell context, E2F1 can activate (Inoshita et al. 1999) or depress (Watanabe et al. 1998) cyclin D1

expression. High level of free E2F1 protein can induce proliferation then apoptosis (Knezevic and Brash 2004). Transgenic mice expressing high level E2F1 also induce apoptosis (Pierce et al. 1998a). In this context, free E2F1 can depress cyclin D1, which formed a negative feedback loop to avoid apoptosis (Watanabe et al. 1998). The last feedback loop is that free E2F1 proteins can activate cyclin D1 (Fan and Bertino 1997). The high level free E2F1 protein can activate another set of genes, e.g., FGFR which let cell cycle progression or transformed cells (Tashiro et al. 2003). The affinity of E2F1 to cyclin D1 promoter is higher than E2F4 (Lee et al. 2000). E2F1 has more potent activator activity than E2F4 (Pierce et al. 1998b). E2F-4 is located in nucleus from G0 until mid-G1 phase and mainly cytoplasmic in late G1, S, and G2 phases. In contrast, endogenous E2F-1 is absent from resting cells and is predominantly nuclear in late G1 and S (Muller et al. 1997). Due to the different affinity, at early stage E2F4 bounding that induce cell cycle entrance, and at late stage E2F1 take place of E2F4 results in cell cycle progression or transformation.

When depression of cyclin D1 promoter by E2F1, the SP1/2/3 is needed (Watanabe et al. 1998). Sp1 is inducible in early–mid-G1 phase (Nagata et al. 2001). In conclusion, E2F4 activate cyclin D1 promoter whereas E2F1 can activate or depress cyclin D1 promoter due to cell context.

NF- κ B

NF- κ B contributes to cell cycle progression, and one of its targets might be cyclin D1 in T47D cell (Hinz et al. 1999). Dbl and Dbs regulated transcription from the cyclin D1 promoter in a NF- κ B-dependent manner (Whitehead et al. 1999). Examination of the sequence from the human cyclin D1 promoter identified potential NF- κ B-binding sites at positions –858, –749, and –39 that matched the NF- κ B consensus binding sequence, GGG(G/A)NNYYCC (Guttridge et al. 1999). Different NF- κ B complex members, p65 p50 and p52, can bind these sites (Guttridge et al. 1999; Westerheide et al. 2001). Although there are three NF- κ B-binding sites, only the proximal site (–39) may be functional (Guo et al. 2009).

Generally NF- κ B binding can induce cyclin D1 promoter (Joyce et al. 1999), whereas PKC delta depress cyclin D1 through NF- κ B binding to –39 site (Page et al. 2002). Bcl-3, a co-activator with NF- κ B p52 homodimers, was demonstrated to directly activate the cyclin D1 promoter through an NF- κ B binding site (Westerheide et al. 2001), whereas p53 represses cyclin D1 transcription through this site under UV treatment downregulating of Bcl-3 (Rocha et al. 2003). Data also showed p53 can inhibit cyclin D1 promoter under heat shock (Guo et al. 2009). So stress stimulations may depress cyclin D1 through the proximal NF- κ B binding site.

CREB/ATF2

The cAMP can inhibit or induce cell cycle progression and cyclin D1 expression. The CRE/ATF2 binding consensus site in cyclin D1 promoter locates at –57 (D'Amico et al. 2000; Lee et al. 1999; Musa et al. 1999; Watanabe et al. 1996a), which can bind CRE/ATF2 (D'Amico et al. 2000; Lee et al. 1999; McMahon et al. 1999; Musa et al. 1999), c-Jun (ATF-2/c-Jun heterodimers; Sabbah et al. 1999), CREM1 (Page et al. 2002), ATF1 (Schneider et al. 2002), and c-Fos (Brown et al. 1998). The effector of Wnt signal transduction pathway, β -catenin/Tcf4, can also bind this site to induce cyclin D1 promoter (Pradeep et al. 2004). Galectin-3 (Lin et al. 2002) and G-17 (Pradeep et al. 2004) induces the cyclin D1 promoter also via the CREB site. Cyclosporine effective element overlaps the element and confers cyclosporine sensitivity to the cyclin D1 promoter (Schneider et al. 2002). PPAR gamma2 (Sharma et al. 2004), PKCdelta (Page et al. 2002) and p16INK4a (D'Amico et al. 2004) can inhibit cyclin D1 promoter through this site.

CREB Ser 133 phosphorylation is necessary for induction of cyclin D1 promoter through this site (D'Amico et al. 2000; Lee et al. 1999; Sharma et al. 2004), but the POU domain of oct-1 can potent its activation without Ser 133 phosphorylation by protein interaction (Boulon et al. 2002). But CREB Ser 133 phosphorylation may result in repression of cyclin D1 due to cell type (Musa et al. 1999).

TCF4

Nuclear β -catenin expression was correlated with cyclin D1 overexpression (Saito et al. 2001; Shtutman et al. 1999; Utsunomiya et al. 2001) with promoting malignant transformation by triggering cyclin D1 expression (Behrens 2000; Brabletz et al. 1999, 2000, Graham and Asthagiri 2004; Jung et al. 2004; Lepourcelet et al. 2004; Morin 1999; Muller-Tidow et al. 2004). TCF4 (Graham and Asthagiri 2004) and β -catenin (Shtutman et al. 1999) activate the cyclin D1 promoter via the consensus TCF/LEF-binding sites (Grueneberg et al. 2003; Holnthoner et al. 2002; Tetsu and McCormick 1999). In addition to TCF4 mainly (Gotoh et al. 2003), LEF-1 (Grueneberg et al. 2003), HBPI (Sampson et al. 2001), and UBF2 (Grueneberg et al. 2003) can also affect the cyclin D1 promoter activity by interaction with β -catenin or LEF-1.

β -catenin is a key component in the canonical Wnt pathway (D'Amico et al. 2000). Some molecules in addition to wnt, such as IKK α (Albanese et al. 2003), PTEN (Persad et al. 2001b), and SOX17 (Lange et al. 2009) can also regulate it. In addition to Wnt pathway, PI3k signal transduction pathway (Albanese et al. 2003; D'Amico et al. 2000), ILK (D'Amico et al. 2000; Persad et al. 2001b), RA (Shah et al. 2002), caveolin-1 (Hulit et al. 2000) can also

regulate cyclin D1 promoter activity via consensus this site in cyclin D1 promoter, and CREB site (Pradeep et al. 2004) may be needed.

E box

There is an E box element at –558 in human cyclin D1 promoter (Eto 2000; Magne et al. 2003; Zhang et al. 2002). The E box can bind Myc or other transcription factor, so some paper may assigned it c-myc element. Myc proteins bind to cyclin D1 promoter to inhibit its activity (Chien et al. 2008; Gonzalez-Mariscal et al. 2009; Philipp et al. 1994), probably inducing DNA methylation (Hervouet et al. 2009). The element may activate cyclin D1 promoter by different protein interaction with myc, e.g., Max (Yang et al. 2009).

Ets

In the proximal region of cyclin D1 promoter, an Ets (c-Ets2) site was first identified in 1995 (Albanese et al. 1995). There several putative Ets binding site in cyclin D1 promoter. Tetsu and McCormick (1999) demonstrated four other Ets sites which they named Ets A B C D, but only the B box is mediated by P21RAS. Zhao et al. (2001) demonstrated that the EtsB binding site mediated cyclin D1 promoter regulation by FAK. The proximal box can mediated PKC delta activity (Page et al. 2002), and RAS induced MAPK signal transduction (Albanese et al. 1995).

CSL

Notch, an evolution-conserved membrane crossed-signal molecular (for review, see Artavanis-Tsakonas et al. 1999) encoding a family of transmembrane proteins that are involved in many cellular processes such as differentiation, proliferation, and apoptosis, can activated cyclin D1 promoter transcription through a CSL site (Jeffries et al. 2002; Ronchini and Capobianco 2001; Stahl et al. 2006).

GT box

There are four GT box in cyclin D1 promoter but only the GT box A was active which was responsible for the inhibition effect of KLF8 to cyclin D1 promoter (Zhao et al. 2003).

Egr-1

In cyclin D1 promoter, Egr-1 site which overlaps two sp1 sites, can mediate TGF β (Yan et al. 1997) and Ang II (Guillemot et al. 2001)-induced cyclin D1 upregulation. But unexpectedly the Egr-1 binding activity to the cyclin D1 promoter is not influenced by SP1 binding (Yan et al. 1997).

Sp1

The transcription factor SP1 is a DNA-binding protein which interacts with a variety of gene promoters containing GC-box elements. Among many possible SP1 sites, the site studied in the promoter overlaps with Egr-1. Induction of the cyclin D1 promoter activity in the early to mid G 1 phase is via the SP1 sites by the Ras-dependent pathway (Nagata et al. 2001). NeuT can induce cyclin D1 promoter by Sp1/3 binding in cooperation with E2F site (Lee et al. 2000). In PC12 cells NGF can induce neurite outgrowth and cyclin D1 transcription via Sp1 and NF- κ B binding site in the proximal region of the cyclin D1 promoter (Marampon et al. 2008).

CycY

The motif is SP1-like but bind basic transcription element binding factor (BTEB) whose molecular weight is smaller than SP1 (Hsiang and Straus 2002). But binding BTEB on CycY site is not responsible for cyclopentenon (Hsiang and Straus 2002).

ARE

p19ARF repressed cyclin D1 through a novel distal *cis*-element ARE at –1137, which bound p53 revealed by chromatin-immunoprecipitation assays (D'Amico et al. 2004). P53 can also repress cyclin D1 promoter in –39 NF- κ B site and HADC1 may involved (Guo et al. 2009; Rocha et al. 2003).

Complex motif

Complex motif here means that two elements in a promoter are very close, sometimes joined together. In this promoter, e.g., E2F and sp1, stat and oct-1 are close to form complex motifs. More often, the proteins that bound to complex motif could interact with each other. So we can deduce that proteins which can interact with each other may result in DNA sequence rearrangement. The protein and DNA sequence can co-evolve.

Starting site

Different groups studied the transcription star site with different methods (Herber et al. 1994a; Hsiang and Straus 2002; Motokura and Arnold 1993; Philipp et al. 1994). Among these, CCTCCAGAGGGCTGT (Motokura and Arnold 1993) and CCTCCAGAGGGCTGT (Hsiang and Straus 2002; transcription star site is underlined) were prevalently accepted. In this review, elements positions were normalized to CCTCCAGAGGGCTGT (Motokura and Arnold 1993).

Signal transduction pathway

There are mainly three signal transduction pathways involved in cyclin D1 promoter regulation, which are MAPK, PI3K/Akt, and Wnt. Others such as ER, NF- κ B, JAK/STAT, Rac1/NADPH oxidase are also involved. Here, we discuss the main three pathways: MAPK, PI3K/Akt and Wnt including its molecules, response elements and cross-talk points (Fig. 2).

ERK1/2 cascade can activate cyclin D1 promoter activity. Raf/Mek/Erk pathway usually activates cyclin D1 promoter (Chu et al. 2005; Greulich and Erikson 1998; Page et al. 1999a, b; Ramakrishnan et al. 1998; Watanabe et al. 1996a, b; Weber et al. 1997a, b). There are two phases of ERK activation, of which the second sustained phase is required for activation of cyclin D1 promoter (Fassett et al. 2003; Talarmin et al. 1999; Treinies et al. 1999; Weber et al. 1997b). But the prolonged ERK activation results in downregulation of cyclin D1 due to inhibition of CREB activity, including its DNA binding ability and Ser-133 phosphorylation (Wang et al. 2003), or due to ERK nuclear location (Burch et al. 2004; Clark et al. 2004). P38 usually inhibits (Catalano et al. 2004; Ellinger-Ziegelbauer et al. 1999; Kintscher et al. 2003; Lavoie et al. 1996; Lee et al. 1999; Page et al. 2001; Pruitt et al. 2002; Todd et al. 2004; Westwick et al. 1998) and sometimes activates (Klein et al. 2003; Lee et al. 2000, 1999; Recio and Merlino 2002) cyclin D1. SV 40 small antigen can induce cyclin D1 promoter by ERK and SAPK pathway (Watanabe et al. 1996a). JNK can activate cyclin D1 promoter via activating c-jun (Oktay et al. 1999; Wulf et al. 2001) and ATF2, which can be by binding CREB/ATF2 site (Lee et al. 1999). But some literatures reported JNK also inhibited cyclin D1




Fig. 2 The main three signal transduction pathways on human cyclin D1 promoter. Three pathways are MAPK, PI3k/Akt, and Wnt. MAPK pathways regulate cyclin D1 promoter via AP-1 and Ets elements. Elements such as LEF/TCF and CRE are responsible for PI3k/Akt and Wnt pathways and GSK3 β is their cross-talk point. PTEN can cross-talk between MAPK and PI3k/Akt pathway

promoter (Grosch et al. 2003) or had no function on cyclin D1 expression in bovine tracheal myocytes (Page et al. 1999a).

ERK pathway induces cyclin D1 promoter by Ets or AP-1 (Chu et al. 2005) elements in cyclin D1 promoter (Albanese et al. 1995; Chu et al. 2005; Guillemot et al. 2001). V-src activation of cyclin D1 involved the ERK, p38, and JNK via CREB site (Lee et al. 1999), but in CCL39 cells, ERK5 but not the ERK1/2 cascade regulate cyclin D1 promoter via this site (Mulloy et al. 2003).

The Wnt signaling pathway is conserved in various organisms from worms to mammals, and plays important roles in development, cellular proliferation, and differentiation. Wnt stabilizes cytoplasmic β -catenin and then β -catenin is translocated into the nucleus where it stimulates the expression of genes including cyclin D1 (Kikuchi 2000; Shtutman et al. 1999; Tetsu and McCormick 1999). PI3k/Akt signal transduction pathway can inhibit GSK3 β and then promote β -catenin to activate cyclin D1 promoter via the TCF site (Albanese et al. 2003). PI3k/Akt signal transduction pathway can also activate cyclin D1 promoter by modulating CREB via its binding site. But this may be weaker than that by inhibition of GSK3 β (Xie et al. 2003). ILK and PDK1 can activate Akt by phosphorylation at different amino acid sites, ser-473 and ser-308, respectively (Persad et al. 2001a), which all take part in Akt activation which consequently then inhibits GSK3 β at ser-9 (Troussard et al. 2003). In some cell type, PKC but not Akt can inhibit GSK3 β (Xie et al. 2003). Rac1 which can form positive regulation loop with PI3k (Welch et al. 2003), can activate cyclin D1 by NF- κ B (Joyce et al. 1999) and CREB site (Bauerfeld et al. 2001; Joyce et al. 1999; Page et al. 2000) independent of ERK (Page et al. 1999b, 2000). Wnt pathway regulation whereby activation of Rac1 amplifies the signaling activity of stabilized/mutated β -catenin by promoting its accumulation in the nucleus, and synergizing with β -catenin to augment TCF/LEF-dependent gene transcription (Esufali and Bapat 2004). PI3k/Akt signal transduction pathway plays important role in regulation of cyclin D1 promoter. The pathway may induce cyclin D1 by CREB site in the promoter and can modulate GSK3 β to activate β -catenin, which can induce cyclin D1. There are many interlinks between PI3k and wnt pathway in regulation of cyclin D1 promoter.

It is usually thought that MAPK, unlike wnt, distinct from PI3k signal transduction pathway (Page et al. 2000), but there are still many cross-talks between them. The ERK pathway modulated AKT phosphorylation by acting on the PTEN levels (Marino et al. 2003). Persad et al. (2001b) define a pathway that ILK and GSK-3 can regulate β -catenin stability, nuclear β -catenin expression, and its transcriptional activity. Wnt-transactivated ErbB1 was responsible for MAPK activation and the increased levels

of cyclin D1 present in the Wnt-expressing HC11 cells (Civenni et al. 2003). TGF- β 1 also first decreases and later potentiates the levels of EGF-activated MEK1/MAPK and PKB, which results in initially suppresses EGF-induced cyclin D1 expression then later releases the inhibition (Yan et al. 2000) implying there are other cross-talks between MAPK and PI3k/Akt.

Taken together, there are cross-talks between Wnt and PI3k usually converging at GSK3 β . MAPK pathway is generally distinct from PI3k, but they can cross-talk, e.g., by PTEN (Marino et al. 2003; Weng et al. 2001), TGF- β 1 (Yan et al. 2000), PAK (Nheu et al. 2004), or others. PTEN is also involved in the regulation of nuclear β -catenin accumulation and TCF transcriptional activation in an APC-independent manner (Persad et al. 2001b). Sometimes in the mammary gland Wnt pathway can activate cyclin D1 by MAPK activation (Civenni et al. 2003).

The temporal expression of cyclin D1

Cell cycle progression requires different signal molecules function at the right time. The stimulation from growth factor is temporal, biphasic (Jones and Kazlauskas 2001). So what pathway function at what time is critical for cell cycle progression. Rac/Cdc42 signaling induces cyclin D1 expression in an early G1 phase. In the mid-G1 phase, cyclin D1 is induced by sustained ERK, which can be promoted by Rho kinase. At the same time, Rho kinase suppresses Rac/Cdc42 activity (Roovers and Assoian 2003; Roovers et al. 2003; Welsh et al. 2001). MKP, as an inhibitor of ERK, can form a feedback loop to a flexibly balanced ERK activity (Bennett and Tonks 1997; Bhalla et al. 2002; Ryser et al. 2004). MKP overexpression can result in downregulation of cyclin D1 (Kawanaka et al. 2001; Lavoie et al. 1996; Qin et al. 2005). In the later stages of G1, PI3k pathways instead of ERK to sustain cyclin D1 expression to perform S phase entry (Gille and Downward 1999; Marino et al. 2003). Akt/PKB, an important downstream of PI3k, is expressed in late G1phase (Gille and Downward 1999; Paramio et al. 1999), but it only influences partly cyclin D1 expression (Gille and Downward 1999). So there may be multiple signal molecules involved.

Epigenetic regulation of the cyclin D1 transcription

Epigenetic regulation means a heritable alteration in gene expression without the primary DNA sequence changing. The major mechanisms involved in epigenetic changes are modification of DNA and histone protein such as DNA methylation at cytosine bases and histone acetylation.

Epigenetic modification sites involved in cyclin D1 transcriptional regulation include (1) GC-rich Sp1/CRE

binding site, (2) remote upstream region mainly in chromosome translocation, a common cause of blood tumor, (3) 1 kb upstream including E-box element, and (4) other DNA methylation sites which have not been studied. Actually, function of DNA methylation and histone modification are commonly studied together.

DNA methylation at Sp1/CRE binding sites of rat cyclin D1 promoter may be essential for keeping a number of the stromal cells in the basal layer live (Kitazawa et al. 1999). In hamster cell, using human cyclin D1 promoter, data showed that DNA methylation was found at Sp1/CRE binding sites (Hilton et al. 2005). However, the epigenetic modification including DNA methylation at cytosine bases and H3/H4 acetylation at Sp1/CRE binding sites may not be essential for transcriptional regulation of cyclin D1 (Krieger et al. 2005). Chromosome translocation, a common cause of blood tumor, is thought to transcriptional regulation of cyclin D1. Data showed that such epigenetic modifications mainly were found in the translocation region, distal upstream region of cyclin D1 promoter (120 kb from the transcriptional start site; Liu et al. 2004) and demethylation may due to CTCF and NPM (Liu et al. 2008a). Different group found the DNA methylation or histone acetylation in this region from different blood tumor including MCL, MM, and NHL and so on. Although the epigenetic modification may be essential in gene transcriptional regulation, it was thought that the epigenetic modification have no effect on cyclin D1 transcription. No DNA methylation was found in cyclin D1 promoter by genomewide methylation analysis in MCL patients (Leshchenko et al. 2010). The endogenous cyclin D1 promoter may be inaccessible to the transcription factor and cyclin D1 transcription may be control through other different manner. Actually the MYEOV gene which located approach to cyclin D1 was transregulated by this epigenetic modification (Janssen et al. 2002), which showed that epigenetic regulation may need a proper transcriptional status. Interestingly, in some MM and MCL samples that did not express cyclin D1, the cyclin D1 promoter was hypomethylated and hyperacetylated, which suggested that DNA methylation in the promoter may be related to malignant phase rather than to cyclin D1 regulation (Liu et al. 2004). And this agreed with the data in NHL research, in which the DNA methylation was identified as a tumor maker, although it is not involved in cyclin D1 transcription (Shi et al. 2007), which showed that the region was proven to be methylated. Genes other than cyclin D1 may be regulated by DNA methylation which can then regulated cyclin D1 including CDKN2A (Vonlanthen et al. 1998; Kawauchi et al. 2004; Takahira et al. 2004; Hutter et al. 2006; Liu et al. 2008b; Matsuda 2008; Takahira et al. 2004; Kawauchi et al. 2004; Hashiguchi et al. 2001; Hutter et al. 2006; Dominguez et al. 2002), wnt (Fox et al. 2008; Martin et al. 2009), and miRNA (Ilnytsky et al. 2008). Data from

blood tumor, epigenetic modification in 1 kb region upstream from transcription start site may not affect cyclin D1 transcription (Liu et al. 2004). Although data from blood tumor cell mainly showed that epigenetic modification may not involved in cyclin D1 transcription, in glioma cells Hhervouet et al. (2009) showed a DNA methylation mechanism in depression of cyclin D1 transcription via E-box, a site-specific DNA methylation site in the 1 kb upstream region of cyclin D1. And different from blood tumor research which showed treatment of TSA or 5-Aza had no effect on cyclin D1 transcription (Krieger et al. 2005), data showed that the epigenetic reagent can regulate its transcription or translation in glioma cell, H1299 cell, follicular lymphoma (also blood tumor) cell and MCF-7 cell (Alao 2007; Alao et al. 2006a, b; Bennett et al. 2009; Hervouet et al. 2009; Rocha et al. 2003). Data from HCC (primary liver cancer) showed DNA methylation in cyclin D1 promoter (Matsuda 2008) and in lung cancer, DNA methylation of CDKN2A promoter in regulation of cyclin D1 may be different (Zhou et al. 2001). So epigenetic regulation may be different due to cell types. Other than histone acetylation, histone methylation of H3k9 may inhibit human (Krieger et al. 2005) and mouse (Shirato et al. 2009) cyclin D1 transcription, and this may function in development (Ait-Si-Ali et al. 2004). Considering CpG islands identifying, other sites may be studied to reveal the epigenetic regulation mechanism involved in cyclin D1 for example there are many other CpG inlands (Krieger et al. 2005) except for the region mentioned above.

In conclusion, epigenetic modification (DNA methylation and histone modification) involved in cyclin D1 transcriptional regulation may be cell type-specific. In most blood tumor, cyclin D1 transcription is not due to DNA or histone modification, but this was not the barrier for the DNA methylation to be used as a putative tumor marker. Other gene (especially CDKN2A) may be regulated by epigenetic modification. There may be other epigenetic modification which can be studied to provide insight into a new mechanism of epigenetic transcriptional regulation of cyclin D1, for there are other CpG islands not studied yet.

Conclusion

Cell cycle control is complex, in which cyclin D1 transcription regulation may be important. But firstly, cell cycle control is not only in transcription level but also in post-transcriptionally regulated manner, e.g., protein degradation, modification, which all play an important role in cell cycle control. For example, GSK3 β can also increase cyclin D1 protein degradation (Hamelers et al. 2002; Jirmanova et al. 2002; Kim et al. 2002; Zou et al. 2004), and cyclin D1 mRNA half-life becomes shorter when

serum is removed (Guo et al. 2005). And secondly, much study got from synchronized cell by serum deprivation, which cannot reflect the real cycle. In actively cycling cells, cyclin D1 may be induced to high levels in G2 phase, and the expression levels of cyclin D1 in G2 phase determine the fate of the next cell cycle (Guo et al. 2005; Stacey 2003). Thirdly, some cell can proliferate and organ developed without cyclin D1 (Kozar et al. 2004; Malumbres et al. 2004). Taken together, the regulation of cyclin D1 promoter is important in cell cycle control, but it is not all.

Acknowledgment The research was supported by foundation from National Nature Science Foundation of China (31050010), Hebei Education Department (2010154) and North China Medical College (BS06002).

References

- Ait-Si-Ali S, Guasconi V, Fritsch L, Yahi H, Sekhri R, Naguibneva I, Robin P, Cabon F, Poleskaya A, Harel-Bellan A (2004) A Suv39h-dependent mechanism for silencing S-phase genes in differentiating but not in cycling cells. *EMBO J* 23:605–615
- Alao JP (2007) The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention. *Mol Cancer* 6:24
- Alao JP, Gamble SC, Stavropoulou AV, Pomeranz KM, Lam EW, Coombes RC, Vigushin DM (2006a) The cyclin D1 proto-oncogene is sequestered in the cytoplasm of mammalian cancer cell lines. *Mol Cancer* 5:7
- Alao JP, Stavropoulou AV, Lam EW, Coombes RC, Vigushin DM (2006b) Histone deacetylase inhibitor, trichostatin A induces ubiquitin-dependent cyclin D1 degradation in MCF-7 breast cancer cells. *Mol Cancer* 5:8
- Albanese C, Johnson J, Watanabe G, Eklund N, Vu D, Arnold A, Pestell RG (1995) Transforming p21ras mutants and c-Ets-2 activate the cyclin D1 promoter through distinguishable regions. *J Biol Chem* 270:23589–23597
- Albanese C, D'Amico M, Reutens AT, Fu M, Watanabe G, Lee RJ, Kitsis RN, Henglein B, Avantiaggiati M, Somasundaram K et al (1999) Activation of the cyclin D1 gene by the E1A-associated protein p300 through AP-1 inhibits cellular apoptosis. *J Biol Chem* 274:34186–34195
- Albanese C, Wu K, D'Amico M, Jarrett C, Joyce D, Hughes J, Hulit J, Sakamaki T, Fu M, Ben-Ze'ev A et al (2003) IKK α regulates mitogenic signaling through transcriptional induction of cyclin D1 via Tcf. *Mol Biol Cell* 14:585–599
- Allan AL, Albanese C, Pestell RG, LaMarre J (2001) Activating transcription factor 3 induces DNA synthesis and expression of cyclin D1 in hepatocytes. *J Biol Chem* 276:27272–27280
- Artavanis-Tsakonas S, Rand MD, Lake RJ (1999) Notch signaling: cell fate control and signal integration in development. *Science* 284:770–776
- Bakiri L, Lallemand D, Bossy-Wetzel E, Yaniv M (2000) Cell cycle-dependent variations in c-Jun and JunB phosphorylation: a role in the control of cyclin D1 expression. *EMBO J* 19:2056–2068
- Balmano K, Cook SJ (1999) Sustained MAP kinase activation is required for the expression of cyclin D1, p21Cip1 and a subset of AP-1 proteins in CCL39 cells. *Oncogene* 18:3085–3097
- Bauerfeld CP, Hershenson MB, Page K (2001) Cdc42, but not RhoA, regulates cyclin D1 expression in bovine tracheal myocytes. *Am J Physiol Lung Cell Mol Physiol* 280:L974–L982

- Behrens J (2000) Control of beta-catenin signaling in tumor development. *Ann NY Acad Sci* 910:21–33, discussion 33–25
- Bennett AM, Tonks NK (1997) Regulation of distinct stages of skeletal muscle differentiation by mitogen-activated protein kinases. *Science* 278:1288–1291
- Bennett LB, Schnabel JL, Kelchen JM, Taylor KH, Guo J, Arthur GL, Papageorgio CN, Shi H, Caldwell CW (2009) DNA hypermethylation accompanied by transcriptional repression in follicular lymphoma. *Genes Chromosom Cancer* 48:828–841
- Bhalla US, Ram PT, Iyengar R (2002) MAP kinase phosphatase as a locus of flexibility in a mitogen-activated protein kinase signaling network. *Science* 297:1018–1023
- Bienvenu F, Barre B, Giraud S, Avril S, Coqueret O (2005) Transcriptional regulation by a DNA-associated form of cyclin D1. *Mol Biol Cell* 16(4):1850–1858
- Boulon S, Dantonel JC, Binet V, Vie A, Blanchard JM, Hipskind RA, Philips A (2002) Oct-1 potentiates CREB-driven cyclin D1 promoter activation via a phospho-CREB- and CREB binding protein-independent mechanism. *Mol Cell Biol* 22:7769–7779
- Brabletz T, Jung A, Dag S, Hlubek F, Kirchner T (1999) Beta-catenin regulates the expression of the matrix metalloproteinase-7 in human colorectal cancer. *Am J Pathol* 155:1033–1038
- Brabletz T, Herrmann K, Jung A, Faller G, Kirchner T (2000) Expression of nuclear beta-catenin and c-myc is correlated with tumor size but not with proliferative activity of colorectal adenomas. *Am J Pathol* 156:865–870
- Brockman JL, Schroeder MD, Schuler LA (2002) PRL activates the cyclin D1 promoter via the Jak2/Stat pathway. *Mol Endocrinol* 16:774–784
- Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C, Darnell JE Jr (1999) Stat3 as an oncogene. *Cell* 98:295–303
- Brown JR, Nigh E, Lee RJ, Ye H, Thompson MA, Saudou F, Pestell RG, Greenberg ME (1998) Fos family members induce cell cycle entry by activating cyclin D1. *Mol Cell Biol* 18:5609–5619
- Burch PM, Yuan Z, Loonen A, Heintz NH (2004) An extracellular signal-regulated kinase 1- and 2-dependent program of chromatin trafficking of c-Fos and Fra-1 is required for cyclin D1 expression during cell cycle reentry. *Mol Cell Biol* 24:4696–4709
- Calo V, Migliavacca M, Bazan V, Macaluso M, Buscemi M, Gebbia N, Russo A (2003) STAT proteins: from normal control of cellular events to tumorigenesis. *J Cell Physiol* 197:157–168
- Catalano A, Caprari P, Rodilossi S, Betta P, Castellucci M, Casazza A, Tamagnone L, Procopio A (2004) Cross-talk between vascular endothelial growth factor and semaphorin-3A pathway in the regulation of normal and malignant mesothelial cell proliferation. *FASEB J* 18:358–360
- Chen L, Zeng Y, Yang H, Lee TD, French SW, Corrales FJ, Garcia-Trevijano ER, Avila MA, Mato JM, Lu SC (2004) Impaired liver regeneration in mice lacking methionine adenosyltransferase 1A. *FASEB J* 18:914–916
- Chien J, Narita K, Rattan R, Giri S, Shridhar R, Staub J, Belefod D, Lai J, Roberts LR, Molina J et al (2008) A role for candidate tumor-suppressor gene TCEAL7 in the regulation of c-Myc activity, cyclin D1 levels and cellular transformation. *Oncogene* 27:7223–7234
- Chu M, Guo J, Chen CY (2005) Long-term exposure to nicotine, via ras pathway, induces cyclin D1 to stimulate G1 cell cycle transition. *J Biol Chem* 280:6369–6379
- Cicatiello L, Addeo R, Sasso A, Altucci L, Petrizzi VB, Borgo R, Cancemi M, Caporali S, Caristi S, Scafoglio C et al (2004) Estrogens and progesterone promote persistent CCND1 gene activation during G1 by inducing transcriptional derepression via c-Jun/c-Fos/estrogen receptor (progesterone receptor) complex assembly to a distal regulatory element and recruitment of cyclin D1 to its own gene promoter. *Mol Cell Biol* 24:7260–7274
- Civenni G, Holbro T, Hynes NE (2003) Wnt1 and Wnt5a induce cyclin D1 expression through ErbB1 transactivation in HC11 mammary epithelial cells. *EMBO Rep* 4:166–171
- Clark JA, Black AR, Leontieva OV, Frey MR, Pysz MA, Kunneva L, Woloszynska-Read A, Roy D, Black JD (2004) Involvement of the ERK signaling cascade in protein kinase C-mediated cell cycle arrest in intestinal epithelial cells. *J Biol Chem* 279:9233–9247
- Coqueret O (2002) Linking cyclins to transcriptional control. *Gene* 299:35–55
- D’Amico M, Hulit J, Amanatullah DF, Zafonte BT, Albanese C, Bouzahzah B, Fu M, Augenlicht LH, Donehower LA, Takemaru K et al (2000) The integrin-linked kinase regulates the cyclin D1 gene through glycogen synthase kinase 3beta and cAMP-responsive element-binding protein-dependent pathways. *J Biol Chem* 275:32649–32657
- D’Amico M, Wu K, Fu M, Rao M, Albanese C, Russell RG, Lian H, Bregman D, White MA, Pestell RG (2004) The inhibitor of cyclin-dependent kinase 4a/alternative reading frame (INK4a/ARF) locus encoded proteins p16INK4a and p19ARF repress cyclin D1 transcription through distinct *cis* elements. *Cancer Res* 64:4122–4130
- Dominguez G, Carballido J, Silva J, Silva JM, Garcia JM, Menendez J, Provencio M, Espana P, Bonilla F (2002) p14ARF promoter hypermethylation in plasma DNA as an indicator of disease recurrence in bladder cancer patients. *Clin Cancer Res* 8:980–985
- Ellinger-Ziegelbauer H, Kelly K, Siebenlist U (1999) Cell cycle arrest and reversion of Ras-induced transformation by a conditionally activated form of mitogen-activated protein kinase kinase 3. *Mol Cell Biol* 19:3857–3868
- Ezufali S, Bapat B (2004) Cross-talk between Rac1 GTPase and dysregulated Wnt signaling pathway leads to cellular redistribution of beta-catenin and TCF/LEF-mediated transcriptional activation. *Oncogene* 23:8260–8271
- Eto I (2000) Molecular cloning and sequence analysis of the promoter region of mouse cyclin D1 gene: implication in phorbol ester-induced tumour promotion. *Cell Prolif* 33:167–187
- Fan J, Bertino JR (1997) Functional roles of E2F in cell cycle regulation. *Oncogene* 14:1191–1200
- Fassett JT, Tobolt D, Nelsen CJ, Albrecht JH, Hansen LK (2003) The role of collagen structure in mitogen stimulation of ERK, cyclin D1 expression, and G1-S progression in rat hepatocytes. *J Biol Chem* 278:31691–31700
- Fox KE, Colton LA, Erickson PF, Friedman JE, Cha HC, Keller P, MacDougald OA, Klemm DJ (2008) Regulation of cyclin D1 and Wnt10b gene expression by cAMP-responsive element-binding protein during early adipogenesis involves differential promoter methylation. *J Biol Chem* 283:35096–35105
- Fu M, Wang C, Li Z, Sakamaki T, Pestell RG (2004) Minireview: Cyclin D1: normal and abnormal functions. *Endocrinology* 145:5439–5447
- Gille H, Downward J (1999) Multiple ras effector pathways contribute to G(1) cell cycle progression. *J Biol Chem* 274:22033–22040
- Gonzalez-Mariscal L, Tapia R, Huerta M, Lopez-Bayghen E (2009) The tight junction protein ZO-2 blocks cell cycle progression and inhibits cyclin D1 expression. *Ann NY Acad Sci* 1165:121–125
- Gotoh J, Obata M, Yoshie M, Kasai S, Ogawa K (2003) Cyclin D1 over-expression correlates with beta-catenin activation, but not with H-ras mutations, and phosphorylation of Akt, GSK3 beta and ERK1/2 in mouse hepatic carcinogenesis. *Carcinogenesis* 24:435–442
- Graham NA, Asthagiri AR (2004) Epidermal growth factor-mediated T-cell factor/lymphoid enhancer factor transcriptional activity is essential but not sufficient for cell cycle progression in non-transformed mammary epithelial cells. *J Biol Chem* 279:23517–23524

- Greulich H, Erikson RL (1998) An analysis of Mek1 signaling in cell proliferation and transformation. *J Biol Chem* 273:13280–13288
- Grosch S, Tegeder I, Schilling K, Maier TJ, Niederberger E, Geisslinger G (2003) Activation of c-Jun-N-terminal-kinase is crucial for the induction of a cell cycle arrest in human colon carcinoma cells caused by flurbiprofen enantiomers. *FASEB J* 17:1316–1318
- Greeneberg DA, Pablo L, Hu KQ, August P, Weng Z, Papkoff J (2003) A functional screen in human cells identifies UBF2 as an RNA polymerase II transcription factor that enhances the beta-catenin signaling pathway. *Mol Cell Biol* 23:3936–3950
- Guillemot L, Levy A, Raymondjean M, Rothhut B (2001) Angiotensin II-induced transcriptional activation of the cyclin D1 gene is mediated by Egr-1 in CHO-AT(1A) cells. *J Biol Chem* 276:39394–39403
- Guo Y, Harwalkar J, Stacey DW, Hitomi M (2005) Destabilization of cyclin D1 message plays a critical role in cell cycle exit upon mitogen withdrawal. *Oncogene* 24:1032–1042
- Guo Z, Wang J, Yang J, Wu NH, Zhang Y, Shen YF (2009) An inhibitory role of p53 via NF-kappaB element on the cyclin D1 gene under heat shock. *Biochim Biophys Acta* 1789:758–762
- Guttridge DC, Albanese C, Reuther JY, Pestell RG, Baldwin AS Jr (1999) NF-kappaB controls cell growth and differentiation through transcriptional regulation of cyclin D1. *Mol Cell Biol* 19:5785–5799
- Hamelers IH, van Schaik RF, Sipkema J, Sussenbach JS, Steenbergh PH (2002) Insulin-like growth factor I triggers nuclear accumulation of cyclin D1 in MCF-7 S breast cancer cells. *J Biol Chem* 277:47645–47652
- Hashiguchi Y, Tsuda H, Yamamoto K, Inoue T, Ishiko O, Ogita S (2001) Combined analysis of p53 and RB pathways in epithelial ovarian cancer. *Hum Pathol* 32:988–996
- Herber B, Truss M, Beato M, Muller R (1994a) Inducible regulatory elements in the human cyclin D1 promoter. *Oncogene* 9:1295–1304
- Herber B, Truss M, Beato M, Muller R (1994b) Inducible regulatory elements in the human cyclin D1 promoter. *Oncogene* 9:2105–2107
- Hervouet E, Vallette FM, Cartron PF (2009) Dnmt3/transcription factor interactions as crucial players in targeted DNA methylation. *Epigenetics* 4:487–499
- Hilton TL, Li Y, Dunphy EL, Wang EH (2005) TAF1 histone acetyltransferase activity in Sp1 activation of the cyclin D1 promoter. *Mol Cell Biol* 25:4321–4332
- Hinz M, Krappmann D, Eichten A, Heder A, Scheiderei C, Strauss M (1999) NF-kappaB function in growth control: regulation of cyclin D1 expression and G0/G1-to-S-phase transition. *Mol Cell Biol* 19:2690–2698
- Holthoner W, Pillinger M, Groger M, Wolff K, Ashton AW, Albanese C, Neumeister P, Pestell RG, Petzelbauer P (2002) Fibroblast growth factor-2 induces Lef/Tcf-dependent transcription in human endothelial cells. *J Biol Chem* 277:45847–45853
- Hsiang CH, Straus DS (2002) Cyclopentenone causes cell cycle arrest and represses cyclin D1 promoter activity in MCF-7 breast cancer cells. *Oncogene* 21:2212–2226
- Hulit J, Bash T, Fu M, Galbiati F, Albanese C, Sage DR, Schlegel A, Zhurinsky J, Shtutman M, Ben-Ze'ev A et al (2000) The cyclin D1 gene is transcriptionally repressed by caveolin-1. *J Biol Chem* 275:21203–21209
- Hutter G, Scheubner M, Zimmermann Y, Kalla J, Katzenberger T, Hubler K, Roth S, Hiddemann W, Ott G, Dreyling M (2006) Differential effect of epigenetic alterations and genomic deletions of CDK inhibitors [p16(INK4a), p15(INK4b), p14(ARF)] in mantle cell lymphoma. *Genes Chromosom Cancer* 45:203–210
- Ilnitsky Y, Zemp FJ, Koturbash I, Kovalchuk O (2008) Altered microRNA expression patterns in irradiated hematopoietic tissues suggest a sex-specific protective mechanism. *Biochem Biophys Res Commun* 377:41–45
- Inoshita S, Terada Y, Nakashima O, Kuwahara M, Sasaki S, Marumo F (1999) Roles of E2F1 in mesangial cell proliferation in vitro. *Kidney Int* 56:2085–2095
- Janssen JW, Imoto I, Inoue J, Shimada Y, Ueda M, Imamura M, Bartram CR, Inazawa J (2002) MYEOV, a gene at 11q13, is coamplified with CCND1, but epigenetically inactivated in a subset of esophageal squamous cell carcinomas. *J Hum Genet* 47:460–464
- Jeffries S, Robbins DJ, Capobianco AJ (2002) Characterization of a high-molecular-weight Notch complex in the nucleus of Notch (ic)-transformed RKE cells and in a human T-cell leukemia cell line. *Mol Cell Biol* 22:3927–3941
- Jirmanova L, Afanassieff M, Gobert-Gosse S, Markossian S, Savatier P (2002) Differential contributions of ERK and PI3-kinase to the regulation of cyclin D1 expression and to the control of the G1/S transition in mouse embryonic stem cells. *Oncogene* 21:5515–5528
- Jones SM, Kazlauskas A (2001) Growth factor-dependent signaling and cell cycle progression. *FEBS Lett* 490:110–116
- Joyce D, Bouzahzah B, Fu M, Albanese C, D'Amico M, Steer J, Klein JU, Lee RJ, Segall JE, Westwick JK et al (1999) Integration of Rac-dependent regulation of cyclin D1 transcription through a nuclear factor-kappaB-dependent pathway. *J Biol Chem* 274:25245–25249
- Jung C, Kim RS, Lee SJ, Wang C, Jeng MH (2004) HOXB13 homeodomain protein suppresses the growth of prostate cancer cells by the negative regulation of T-cell factor 4. *Cancer Res* 64:3046–3051
- Kabotyanski EB, Rosen JM (2003) Signal transduction pathways regulated by prolactin and Src result in different conformations of activated Stat5b. *J Biol Chem* 278:17218–17227
- Kawanaka H, Tomikawa M, Baatar D, Jones MK, Pai R, Szabo IL, Sugimachi K, Sarfeh IJ, Tarnawski AS (2001) Despite activation of EGF-receptor-ERK signaling pathway, epithelial proliferation is impaired in portal hypertensive gastric mucosa: relevance of MKP-1, c-fos, c-myc, and cyclin D1 expression. *Life Sci* 69:3019–3033
- Kawauchi S, Liu XP, Kawasaki K, Hirakawa T, Amada S, Furuya T, Oga A, Sasaki K (2004) Significance of beta-catenin and pRB pathway components in malignant ovarian germ cell tumours: INK4A promoter CpG island methylation is associated with cell proliferation. *J Pathol* 204:268–276
- Kijima T, Niwa H, Steinman RA, Drenning SD, Gooding WE, Wentzel AL, Xi S, Grandis JR (2002) STAT3 activation abrogates growth factor dependence and contributes to head and neck squamous cell carcinoma tumor growth in vivo. *Cell Growth Differ* 13:355–362
- Kikuchi A (2000) Regulation of beta-catenin signaling in the Wnt pathway. *Biochem Biophys Res Commun* 268:243–248
- Kim AL, Gautier J, Bickers DR, Athar M (2002) Reduced cyclin D1 ubiquitination in UVB-induced murine squamous cell carcinomas. *Biochem Biophys Res Commun* 298:377–382
- Kintscher U, Bruemmer D, Blaschke F, Unger T, Law RE (2003) p38 MAP kinase negatively regulates angiotensin II-mediated effects on cell cycle molecules in human coronary smooth muscle cells. *Biochem Biophys Res Commun* 305:552–556
- Kitazawa S, Kitazawa R, Maeda S (1999) Transcriptional regulation of rat cyclin D1 gene by CpG methylation status in promoter region. *J Biol Chem* 274:28787–28793
- Klein A, Guhl E, Tzeng YJ, Fuhrhop J, Levrero M, Graessmann M, Graessmann A (2003) HBX causes cyclin D1 overexpression and development of breast cancer in transgenic animals that are heterozygous for p53. *Oncogene* 22:2910–2919
- Knezevic D, Brash DE (2004) Role of E2F1 in apoptosis: a case study in feedback loops. *Cell Cycle* 3:729–732
- Kozar K, Ciemerych MA, Rebel VI, Shigematsu H, Zagodzón A, Sicinska E, Geng Y, Yu Q, Bhattacharya S, Bronson RT et al

- (2004) Mouse development and cell proliferation in the absence of D-cyclins. *Cell* 118:477–491
- Krieger S, Grunau C, Sabbah M, Sola B (2005) Cyclin D1 gene activation in human myeloma cells is independent of DNA hypomethylation or histone hyperacetylation. *Exp Hematol* 33:652–659
- Lamb J, Ramaswamy S, Ford HL, Contreras B, Martinez RV, Kittrell FS, Zahnow CA, Patterson N, Golub TR, Ewen ME (2003) A mechanism of cyclin D1 action encoded in the patterns of gene expression in human cancer. *Cell* 114:323–334
- Lange AW, Keiser AR, Wells JM, Zorn AM, Whitsett JA (2009) Sox17 promotes cell cycle progression and inhibits TGF-beta/Smad3 signaling to initiate progenitor cell behavior in the respiratory epithelium. *PLoS ONE* 4:e5711
- Lavoie JN, L'Allemain G, Brunet A, Muller R, Pouyssegur J (1996) Cyclin D1 expression is regulated positively by the p42/p44MAPK and negatively by the p38/HOGMAPK pathway. *J Biol Chem* 271:20608–20616
- Lee RJ, Albanese C, Stenger RJ, Watanabe G, Inghirami G, Haines GK 3rd, Webster M, Muller WJ, Brugge JS, Davis RJ, Pestell RG (1999) pp 60(v-src) induction of cyclin D1 requires collaborative interactions between the extracellular signal-regulated kinase, p38, and Jun kinase pathways. A role for cAMP response element-binding protein and activating transcription factor-2 in pp60(v-src) signaling in breast cancer cells. *J Biol Chem* 274:7341–7350
- Lee RJ, Albanese C, Fu M, D'Amico M, Lin B, Watanabe G, Haines GK 3rd, Siegel PM, Hung MC, Yarden Y et al (2000) Cyclin D1 is required for transformation by activated Neu and is induced through an E2F-dependent signaling pathway. *Mol Cell Biol* 20:672–683
- Lepourcelet M, Chen YN, France DS, Wang H, Crews P, Petersen F, Bruceo C, Wood AW, Shivdasani RA (2004) Small-molecule antagonists of the oncogenic Tcf/beta-catenin protein complex. *Cancer Cell* 5:91–102
- Leshchenko VV, Kuo PY, Shaknovich R, Yang DT, Gellen T, Petrich A, Yu Y, Remache Y, Weniger MA, Rafiq S et al (2010) Genomewide DNA methylation analysis reveals novel targets for drug development in mantle cell lymphoma. *Blood* 116(7):1025–1034
- Leslie K, Lang C, Devgan G, Azare J, Berishaj M, Gerald W, Kim YB, Paz K, Darnell JE, Albanese C et al (2006) Cyclin D1 is transcriptionally regulated by and required for transformation by activated signal transducer and activator of transcription 3. *Cancer Res* 66:2544–2552
- Lin HM, Pestell RG, Raz A, Kim HR (2002) Galectin-3 enhances cyclin D(1) promoter activity through SP1 and a cAMP-responsive element in human breast epithelial cells. *Oncogene* 21:8001–8010
- Liu H, Wang J, Epner EM (2004) Cyclin D1 activation in B-cell malignancy: association with changes in histone acetylation, DNA methylation, and RNA polymerase II binding to both promoter and distal sequences. *Blood* 104:2505–2513
- Liu H, Huang J, Wang J, Jiang S, Bailey AS, Goldman DC, Welcker M, Bedell V, Slovak ML, Clurman B et al (2008a) Transvection mediated by the translocated cyclin D1 locus in mantle cell lymphoma. *J Exp Med* 205:1843–1858
- Liu T, Niu Y, Feng Y, Niu R, Yu Y, Lv A, Yang Y (2008b) Methylation of CpG islands of p16(INK4a) and cyclinD1 overexpression associated with progression of intraductal proliferative lesions of the breast. *Hum Pathol* 39:1637–1646
- Magne S, Caron S, Charon M, Rouyez MC, Dusanter-Fourt I (2003) STAT5 and Oct-1 form a stable complex that modulates cyclin D1 expression. *Mol Cell Biol* 23:8934–8945
- Malumbres M, Sotillo R, Santamaria D, Galan J, Cerezo A, Ortega S, Dubus P, Barbacid M (2004) Mammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and Cdk6. *Cell* 118:493–504
- Marampon F, Casimiro MC, Fu M, Powell MJ, Popov VM, Lindsay J, Zani BM, Ciccarelli C, Watanabe G, Lee RJ, Pestell RG (2008) Nerve Growth factor regulation of cyclin D1 in PC12 cells through a p21RAS extracellular signal-regulated kinase pathway requires cooperative interactions between Sp1 and nuclear factor-kappaB. *Mol Biol Cell* 19:2566–2578
- Marino M, Acconcia F, Trentalance A (2003) Biphasic estradiol-induced AKT phosphorylation is modulated by PTEN via MAP kinase in HepG2 cells. *Mol Biol Cell* 14:2583–2591
- Martin V, Valencia A, Agirre X, Cervera J, San Jose-Eneriz E, Vilas-Zornoza A, Rodriguez-Otero P, Sanz MA, Herrera C, Torres A et al (2009) Epigenetic regulation of the non-canonical Wnt pathway in acute myeloid leukemia. *Cancer Sci* 101:425–432
- Masuda M, Suzui M, Weinstein IB (2001) Effects of epigallocatechin-3-gallate on growth, epidermal growth factor receptor signaling pathways, gene expression, and chemosensitivity in human head and neck squamous cell carcinoma cell lines. *Clin Cancer Res* 7:4220–4229
- Masuda M, Suzui M, Yasumatu R, Nakashima T, Kuratomi Y, Azuma K, Tomita K, Komiyama S, Weinstein IB (2002) Constitutive activation of signal transducers and activators of transcription 3 correlates with cyclin D1 overexpression and may provide a novel prognostic marker in head and neck squamous cell carcinoma. *Cancer Res* 62:3351–3355
- Matsuda Y (2008) Molecular mechanism underlying the functional loss of cyclindependent kinase inhibitors p16 and p27 in hepatocellular carcinoma. *World J Gastroenterol* 14:1734–1740
- Matsumura I, Kitamura T, Wakao H, Tanaka H, Hashimoto K, Albanese C, Downward J, Pestell RG, Kanakura Y (1999) Transcriptional regulation of the cyclin D1 promoter by STAT5: its involvement in cytokine-dependent growth of hematopoietic cells. *EMBO J* 18:1367–1377
- McMahon C, Suthiphongchai T, DiRenzo J, Ewen ME (1999) P/CAF associates with cyclin D1 and potentiates its activation of the estrogen receptor. *Proc Natl Acad Sci USA* 96:5382–5387
- Mechta R, Lallemand D, Pfarr CM, Yaniv M (1997) Transformation by ras modifies AP1 composition and activity. *Oncogene* 14:837–847
- Morin PJ (1999) beta-catenin signaling and cancer. *Bioessays* 21:1021–1030
- Motokura T, Arnold A (1993) PRAD1/cyclin D1 proto-oncogene: genomic organization, 5' DNA sequence, and sequence of a tumor-specific rearrangement breakpoint. *Genes Chromosom Cancer* 7:89–95
- Muller H, Moroni MC, Vigo E, Petersen BO, Bartek J, Helin K (1997) Induction of S-phase entry by E2F transcription factors depends on their nuclear localization. *Mol Cell Biol* 17:5508–5520
- Muller-Tidow C, Steffen B, Cauvet T, Tickenbrock L, Ji P, Diederichs S, Sargin B, Kohler G, Stelljes M, Puccetti E et al (2004) Translocation products in acute myeloid leukemia activate the Wnt signaling pathway in hematopoietic cells. *Mol Cell Biol* 24:2890–2904
- Mulloy R, Salinas S, Philips A, Hipskind RA (2003) Activation of cyclin D1 expression by the ERK5 cascade. *Oncogene* 22:5387–5398
- Musa NL, Ramakrishnan M, Li J, Kartha S, Liu P, Pestell RG, Hershenon MB (1999) Forskolin inhibits cyclin D1 expression in cultured airway smooth-muscle cells. *Am J Respir Cell Mol Biol* 20:352–358
- Nagata D, Suzuki E, Nishimatsu H, Satonaka H, Goto A, Omata M, Hirata Y (2001) Transcriptional activation of the cyclin D1 gene is mediated by multiple cis-elements, including SP1 sites and a cAMP-responsive element in vascular endothelial cells. *J Biol Chem* 276:662–669

- Nheu T, He H, Hirokawa Y, Walker F, Wood J, Maruta H (2004) PAK is essential for RAS-induced upregulation of cyclin D1 during the G1 to S transition. *Cell Cycle* 3:71–74
- Oktay M, Wary KK, Dans M, Birge RB, Giancotti FG (1999) Integrin-mediated activation of focal adhesion kinase is required for signaling to Jun NH2-terminal kinase and progression through the G1 phase of the cell cycle. *J Cell Biol* 145:1461–1469
- Page K, Li J, Hershenson MB (1999a) Platelet-derived growth factor stimulation of mitogen-activated protein kinases and cyclin D1 promoter activity in cultured airway smooth-muscle cells. Role of Ras. *Am J Respir Cell Mol Biol* 20:1294–1302
- Page K, Li J, Hodge JA, Liu PT, Vanden Hoek TL, Becker LB, Pestell RG, Rosner MR, Hershenson MB (1999b) Characterization of a Rac1 signaling pathway to cyclin D(1) expression in airway smooth muscle cells. *J Biol Chem* 274:22065–22071
- Page K, Li J, Wang Y, Kartha S, Pestell RG, Hershenson MB (2000) Regulation of cyclin D(1) expression and DNA synthesis by phosphatidylinositol 3-kinase in airway smooth muscle cells. *Am J Respir Cell Mol Biol* 23:436–443
- Page K, Li J, Hershenson MB (2001) p38 MAP kinase negatively regulates cyclin D1 expression in airway smooth muscle cells. *Am J Physiol Lung Cell Mol Physiol* 280:L955–L964
- Page K, Li J, Corbit KC, Rumilla KM, Soh JW, Weinstein IB, Albanese C, Pestell RG, Rosner MR, Hershenson MB (2002) Regulation of airway smooth muscle cyclin D1 transcription by protein kinase C-delta. *Am J Respir Cell Mol Biol* 27:204–213
- Paramio JM, Navarro M, Segrelles C, Gomez-Casero E, Jorcano JL (1999) PTEN tumour suppressor is linked to the cell cycle control through the retinoblastoma protein. *Oncogene* 18:7462–7468
- Persad S, Attwell S, Gray V, Mawji N, Deng JT, Leung D, Yan J, Sanghera J, Walsh MP, Dedhar S (2001a) Regulation of protein kinase B/Akt-serine 473 phosphorylation by integrin-linked kinase: critical roles for kinase activity and amino acids arginine 211 and serine 343. *J Biol Chem* 276:27462–27469
- Persad S, Troussard AA, McPhee TR, Mulholland DJ, Dedhar S (2001b) Tumor suppressor PTEN inhibits nuclear accumulation of beta-catenin and T cell/lymphoid enhancer factor 1-mediated transcriptional activation. *J Cell Biol* 153:1161–1174
- Pestell RG, Albanese C, Reutens AT, Segall JE, Lee RJ, Arnold A (1999) The cyclins and cyclin-dependent kinase inhibitors in hormonal regulation of proliferation and differentiation. *Endocr Rev* 20:501–534
- Philipp A, Schneider A, Vasrik I, Finke K, Xiong Y, Beach D, Alitalo K, Eilers M (1994) Repression of cyclin D1: a novel function of MYC. *Mol Cell Biol* 14:4032–4043
- Pierce AM, Fisher SM, Conti CJ, Johnson DG (1998a) Deregulated expression of E2F1 induces hyperplasia and cooperates with ras in skin tumor development. *Oncogene* 16:1267–1276
- Pierce AM, Schneider-Broussard R, Philhower JL, Johnson DG (1998b) Differential activities of E2F family members: unique functions in regulating transcription. *Mol Carcinog* 22:190–198
- Pradeep A, Sharma C, Sathyanarayana P, Albanese C, Fleming JV, Wang TC, Wolfe MM, Baker KM, Pestell RG, Rana B (2004) Gastrin-mediated activation of cyclin D1 transcription involves beta-catenin and CREB pathways in gastric cancer cells. *Oncogene* 23:3689–3699
- Pruitt K, Pruitt WM, Bilter GK, Westwick JK, Der CJ (2002) Raf-independent deregulation of p38 and JNK mitogen-activated protein kinases are critical for Ras transformation. *J Biol Chem* 277:31808–31817
- Qin L, Li X, Ko JK, Partridge NC (2005) Parathyroid hormone uses multiple mechanisms to arrest the cell cycle progression of osteoblastic cells from G1 to S phase. *J Biol Chem* 280:3104–3111
- Quintanilla-Martinez L, Kremer M, Specht K, Calzada-Wack J, Nathrath M, Schaich R, Hofler H, Fend F (2003) Analysis of signal transducer and activator of transcription 3 (Stat 3) pathway in multiple myeloma: Stat 3 activation and cyclin D1 dysregulation are mutually exclusive events. *Am J Pathol* 162:1449–1461
- Ramakrishnan M, Musa NL, Li J, Liu PT, Pestell RG, Hershenson MB (1998) Catalytic activation of extracellular signal-regulated kinases induces cyclin D1 expression in primary tracheal myocytes. *Am J Respir Cell Mol Biol* 18:736–740
- Recio JA, Merlino G (2002) Hepatocyte growth factor/scatter factor activates proliferation in melanoma cells through p38 MAPK, ATF-2 and cyclin D1. *Oncogene* 21:1000–1008
- Rocha S, Martin AM, Meek DW, Perkins ND (2003) p53 represses cyclin D1 transcription through down regulation of Bcl-3 and inducing increased association of the p52 NF-kappaB subunit with histone deacetylase 1. *Mol Cell Biol* 23:4713–4727
- Roche KC, Wiechens N, Owen-Hughes T, Perkins ND (2004) The FHA domain protein SNIP1 is a regulator of the cell cycle and cyclin D1 expression. *Oncogene* 23:8185–8195
- Ronchini C, Capobianco AJ (2001) Induction of cyclin D1 transcription and CDK2 activity by Notch(ic): implication for cell cycle disruption in transformation by Notch(ic). *Mol Cell Biol* 21:5925–5934
- Roovers K, Assoian RK (2003) Effects of rho kinase and actin stress fibers on sustained extracellular signal-regulated kinase activity and activation of G(1) phase cyclin-dependent kinases. *Mol Cell Biol* 23:4283–4294
- Roovers K, Klein EA, Castagnino P, Assoian RK (2003) Nuclear translocation of LIM kinase mediates Rho-Rho kinase regulation of cyclin D1 expression. *Dev Cell* 5:273–284
- Ryser S, Massiha A, Piuz I, Schlegel W (2004) Stimulated initiation of mitogen-activated protein kinase phosphatase-1 (MKP-1) gene transcription involves the synergistic action of multiple *cis*-acting elements in the proximal promoter. *Biochem J* 378:473–484
- Sabbah M, Courilleau D, Mester J, Redeuilh G (1999) Estrogen induction of the cyclin D1 promoter: involvement of a cAMP response-like element. *Proc Natl Acad Sci USA* 96:11217–11222
- Saito T, Oda Y, Tanaka K, Matsuda S, Tamiya S, Iwamoto Y, Tsuneyoshi M (2001) beta-catenin nuclear expression correlates with cyclin D1 overexpression in sporadic desmoid tumours. *J Pathol* 195:222–228
- Sampson EM, Haque ZK, Ku MC, Tevosian SG, Albanese C, Pestell RG, Paulson KE, Yee AS (2001) Negative regulation of the Wnt-beta-catenin pathway by the transcriptional repressor HBP1. *EMBO J* 20:4500–4511
- Schneider G, Oswald F, Wahl C, Greten FR, Adler G, Schmid RM (2002) Cyclosporine inhibits growth through the activating transcription factor/cAMP-responsive element-binding protein binding site in the cyclin D1 promoter. *J Biol Chem* 277:43599–43607
- Shah S, Pishvaian MJ, Easwaran V, Brown PH, Byers SW (2002) The role of cadherin, beta-catenin, and AP-1 in retinoid-regulated carcinoma cell differentiation and proliferation. *J Biol Chem* 277:25313–25322
- Sharma C, Pradeep A, Pestell RG, Rana B (2004) Peroxisome proliferator-activated receptor gamma activation modulates cyclin D1 transcription via beta-catenin-independent and cAMP-response element-binding protein-dependent pathways in mouse hepatocytes. *J Biol Chem* 279:16927–16938
- Shaulian E, Karin M (2001) AP-1 in cell proliferation and survival. *Oncogene* 20:2390–2400
- Shi H, Guo J, Duff DJ, Rahmatpanah F, Chitima-Matsiga R, Al-Kuhlani M, Taylor KH, Sjahputera O, Andreski M, Wooldridge JE, Caldwell CW (2007) Discovery of novel epigenetic markers in non-Hodgkin's lymphoma. *Carcinogenesis* 28:60–70

- Shirato H, Ogawa S, Nakajima K, Inagawa M, Kojima M, Tachibana M, Shinkai Y, Takeuchi T (2009) A jumonji (Jarid2) protein complex represses cyclin D1 expression by methylation of histone H3-K9. *J Biol Chem* 284:733–739
- Shtutman M, Zhurinsky J, Simcha I, Albanese C, D'Amico M, Pestell R, Ben-Ze'ev A (1999) The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. *Proc Natl Acad Sci USA* 96:5522–5527
- Soh JW, Weinstein IB (2003) Roles of specific isoforms of protein kinase C in the transcriptional control of cyclin D1 and related genes. *J Biol Chem* 278:34709–34716
- Stacey DW (2003) Cyclin D1 serves as a cell cycle regulatory switch in actively proliferating cells. *Curr Opin Cell Biol* 15:158–163
- Stahl M, Ge C, Shi S, Pestell RG, Stanley P (2006) Notch1-induced transformation of RKE-1 cells requires up-regulation of cyclin D1. *Cancer Res* 66:7562–7570
- Takahira T, Oda Y, Tamiya S, Yamamoto H, Kawaguchi K, Kobayashi C, Iwamoto Y, Tsuneyoshi M (2004) Alterations of the p16INK4a/p14ARF pathway in clear cell sarcoma. *Cancer Sci* 95:651–655
- Talarmin H, Rescan C, Cariou S, Glaise D, Zanninelli G, Bilodeau M, Loyer P, Guguen-Guillouzo C, Baffet G (1999) The mitogen-activated protein kinase/extracellular signal-regulated kinase cascade activation is a key signalling pathway involved in the regulation of G(1) phase progression in proliferating hepatocytes. *Mol Cell Biol* 19:6003–6011
- Tashiro E, Maruki H, Minato Y, Doki Y, Weinstein IB, Imoto M (2003) Overexpression of cyclin D1 contributes to malignancy by up-regulation of fibroblast growth factor receptor 1 via the pRB/E2F pathway. *Cancer Res* 63:424–431
- Tetsu O, McCormick F (1999) Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. *Nature* 398:422–426
- Todd DE, Densham RM, Molton SA, Balmanno K, Newson C, Weston CR, Garner AP, Scott L, Cook SJ (2004) ERK1/2 and p38 cooperate to induce a p21(CIP1)-dependent G(1) cell cycle arrest. *Oncogene* 23:3284–3295
- Treiniés I, Paterson HF, Hooper S, Wilson R, Marshall CJ (1999) Activated MEK stimulates expression of AP-1 components independently of phosphatidylinositol 3-kinase (PI3-kinase) but requires a PI3-kinase signal To stimulate DNA synthesis. *Mol Cell Biol* 19:321–329
- Troussard AA, Mawji NM, Ong C, Mui A, St-Arnaud R, Dedhar S (2003) Conditional knock-out of integrin-linked kinase demonstrates an essential role in protein kinase B/Akt activation. *J Biol Chem* 278:22374–22378
- Utsunomiya T, Doki Y, Takemoto H, Shiozaki H, Yano M, Sekimoto M, Tamura S, Yasuda T, Fujiwara Y, Monden M (2001) Correlation of beta-catenin and cyclin D1 expression in colon cancers. *Oncology* 61:226–233
- Vonlanthen S, Heighway J, Tschan MP, Borner MM, Altermatt HJ, Kappeler A, Tobler A, Fey MF, Thatcher N, Yarbrough WG, Betticher DC (1998) Expression of p16INK4a/p16alpha and p19ARF/p16beta is frequently altered in non-small cell lung cancer and correlates with p53 overexpression. *Oncogene* 17:2779–2785
- Wang Z, Zhang B, Wang M, Carr BI (2003) Persistent ERK phosphorylation negatively regulates cAMP response element-binding protein (CREB) activity via recruitment of CREB-binding protein to pp 90RSK. *J Biol Chem* 278:11138–11144
- Watanabe G, Howe A, Lee RJ, Albanese C, Shu IW, Karnezis AN, Zon L, Kyriakis J, Rundell K, Pestell RG (1996a) Induction of cyclin D1 by simian virus 40 small tumor antigen. *Proc Natl Acad Sci USA* 93:12861–12866
- Watanabe G, Lee RJ, Albanese C, Rainey WE, Battle D, Pestell RG (1996b) Angiotensin II activation of cyclin D1-dependent kinase activity. *J Biol Chem* 271:22570–22577
- Watanabe G, Albanese C, Lee RJ, Reutens A, Vairo G, Henglein B, Pestell RG (1998) Inhibition of cyclin D1 kinase activity is associated with E2F-mediated inhibition of cyclin D1 promoter activity through E2F and Sp1. *Mol Cell Biol* 18:3212–3222
- Weber JD, Hu W, Jefcoat SC Jr, Raben DM, Baldassare JJ (1997a) Ras-stimulated extracellular signal-related kinase 1 and RhoA activities coordinate platelet-derived growth factor-induced G1 progression through the independent regulation of cyclin D1 and p27. *J Biol Chem* 272:32966–32971
- Weber JD, Raben DM, Phillips PJ, Baldassare JJ (1997b) Sustained activation of extracellular-signal-regulated kinase 1 (ERK1) is required for the continued expression of cyclin D1 in G1 phase. *Biochem J* 326(Pt 1):61–68
- Welch HC, Coadwell WJ, Stephens LR, Hawkins PT (2003) Phosphoinositide 3-kinase-dependent activation of Rac. *FEBS Lett* 546:93–97
- Welsh CF, Roovers K, Villanueva J, Liu Y, Schwartz MA, Assoian RK (2001) Timing of cyclin D1 expression within G1 phase is controlled by Rho. *Nat Cell Biol* 3:950–957
- Weng LP, Smith WM, Brown JL, Eng C (2001) PTEN inhibits insulin-stimulated MEK/MAPK activation and cell growth by blocking IRS-1 phosphorylation and IRS-1/Grb-2/Sos complex formation in a breast cancer model. *Hum Mol Genet* 10:605–616
- Westerheide SD, Mayo MW, Anest V, Hanson JL, Baldwin AS Jr (2001) The putative oncoprotein Bcl-3 induces cyclin D1 to stimulate G(1) transition. *Mol Cell Biol* 21:8428–8436
- Westwick JK, Lee RJ, Lambert QT, Symons M, Pestell RG, Der CJ, Whitehead IP (1998) Transforming potential of Dbl family proteins correlates with transcription from the cyclin D1 promoter but not with activation of Jun NH2-terminal kinase, p38/Mpk2, serum response factor, or c-Jun. *J Biol Chem* 273:16739–16747
- Whitehead IP, Lambert QT, Glaven JA, Abe K, Rossman KL, Mahon GM, Trzaskos JM, Kay R, Campbell SL, Der CJ (1999) Dependence of Dbl and Dbs transformation on MEK and NF-kappaB activation. *Mol Cell Biol* 19:7759–7770
- Wulf GM, Ryo A, Wulf GG, Lee SW, Niu T, Petkova V, Lu KP (2001) Pin1 is overexpressed in breast cancer and cooperates with Ras signaling in increasing the transcriptional activity of c-Jun towards cyclin D1. *EMBO J* 20:3459–3472
- Xie Z, Zeng X, Waldman T, Glazer RI (2003) Transformation of mammary epithelial cells by 3-phosphoinositide-dependent protein kinase-1 activates beta-catenin and c-Myc, and down-regulates caveolin-1. *Cancer Res* 63:5370–5375
- Yan YX, Nakagawa H, Lee MH, Rustgi AK (1997) Transforming growth factor-alpha enhances cyclin D1 transcription through the binding of early growth response protein to a cis-regulatory element in the cyclin D1 promoter. *J Biol Chem* 272:33181–33190
- Yan S, Krebs S, Leister KJ, Wenner CE (2000) Perturbation of EGF-activated MEK1 and PKB signal pathways by TGF-beta1 correlates with perturbation of EGF-induced cyclin D1 and DNA synthesis by TGF-beta1 in C3H 10 T1/2 cells. *J Cell Physiol* 185:107–116
- Yang H, Li TW, Ko KS, Xia M, Lu SC (2009) Switch from Mnt-Max to Myc-Max induces p53 and cyclin D1 expression and apoptosis during cholestasis in mouse and human hepatocytes. *Hepatology* 49:860–870
- Zhang ZK, Davies KP, Allen J, Zhu L, Pestell RG, Zagzag D, Kalpana GV (2002) Cell cycle arrest and repression of cyclin D1 transcription by INI1/hSNF5. *Mol Cell Biol* 22:5975–5988
- Zhang F, Li C, Halfter H, Liu J (2003) Delineating an oncostatin M-activated STAT3 signaling pathway that coordinates the expression of genes involved in cell cycle regulation and extracellular matrix deposition of MCF-7 cells. *Oncogene* 22:894–905

- Zhao J, Pestell R, Guan JL (2001) Transcriptional activation of cyclin D1 promoter by FAK contributes to cell cycle progression. *Mol Biol Cell* 12:4066–4077
- Zhao J, Bian ZC, Yee K, Chen BP, Chien S, Guan JL (2003) Identification of transcription factor KLF8 as a downstream target of focal adhesion kinase in its regulation of cyclin D1 and cell cycle progression. *Mol Cell* 11:1503–1515
- Zhou JX, Niehans GA, Shar A, Rubins JB, Frizelle SP, Kratzke RA (2001) Mechanisms of G1 checkpoint loss in resected early stage non-small cell lung cancer. *Lung Cancer* 32:27–38
- Zou Y, Ewton DZ, Deng X, Mercer SE, Friedman E (2004) Mirk/dyrk1B kinase destabilizes cyclin D1 by phosphorylation at threonine 288. *J Biol Chem* 279:27790–27798